Agios Presents Positive Results from Phase 3 ENERGIZE-T Study of Mitapivat at ASH 2024 and Provides Regulatory Update on MitapivatGlobeNewsWire • 12/08/24
Is Agios Pharmaceuticals (AGIO) Stock Outpacing Its Medical Peers This Year?Zacks Investment Research • 11/26/24
Agios to Present New Data on Mitapivat and Tebapivat in Rare Blood Disorders at 66th ASH Annual Meeting and ExpositionGlobeNewsWire • 11/05/24
Agios Pharmaceuticals (AGIO) Misses Q3 Earnings and Revenue EstimatesZacks Investment Research • 10/31/24
Agios to Webcast Conference Call of Third Quarter 2024 Financial Results on October 31, 2024GlobeNewsWire • 10/17/24
Agios Announces FDA Orphan Drug Designation Granted to Tebapivat (AG-946) for Treatment of Myelodysplastic Syndromes (MDS)GlobeNewsWire • 09/11/24
Agios to Present at the 2024 Cantor Global Healthcare Conference on September 18, 2024GlobeNewsWire • 09/05/24
Agios to Receive $1.1 Billion in Milestone Payments Following FDA Approval of VorasidenibGlobeNewsWire • 08/06/24
Agios Pharmaceuticals' Rare Blood Disorder Drug Misses Primary Goal In Pediatric Study, Stock SlidesBenzinga • 08/01/24
Agios Pharmaceuticals (AGIO) Reports Q2 Loss, Lags Revenue EstimatesZacks Investment Research • 08/01/24
Agios Announces Results from Phase 3 ACTIVATE-KidsT Study of Mitapivat in Children with PK Deficiency Who Are Regularly TransfusedGlobeNewsWire • 08/01/24
Agios to Webcast Conference Call of Second Quarter 2024 Financial Results on August 1, 2024GlobeNewsWire • 07/18/24
Agios Pharmaceuticals (AGIO) Surges 6.5%: Is This an Indication of Further Gains?Zacks Investment Research • 06/24/24
Agios Pharmaceuticals: Potential Acquisition Target, Upcoming FDA Approvals, Promising PipelineSeeking Alpha • 06/12/24